Physician profile
Dennis Riff
NPI 1922004662
$32,682.02
in general payments reported to CMS, 2019-2025
33 companies · $2,205 in 2025
The $2,205 reported for 2025 was more than what 94% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,853 · 2020: $1,118 · 2021: $1,491 · 2022: $1,551 · 2023: $870 · 2024: $23K · 2025: $2,205.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15K · Food and Beverage: $6,280 · Debt Forgiveness: $2,707 · Travel and Lodging: $1,548 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $15,050.00 |
| Food and Beverage | $6,279.81 |
| Debt Forgiveness | $2,706.68 |
| Travel and Lodging | $1,547.54 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $17,851.45 | 2024-2025 | Voquezna |
| Olympus America INC. | $2,706.68 | 2024 | Evis X1 Video System Center |
| Abbvie INC. | $2,612.29 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Pfizer INC. | $2,595.76 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,103.01 | 2019-2025 | Xifaxan, Plenvu |
| Ardelyx, INC. | $976.31 | 2022-2025 | Ibsrela |
| Gilead Sciences, INC. | $826.31 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $714.35 | 2019-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $675.38 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Genzyme Corporation | $293.78 | 2022-2025 | |
| Madrigal Pharmaceuticals | $259.30 | 2024-2025 | Rezdiffra, Resmetirom |
| Lilly USA, LLC | $186.41 | 2024-2025 | Omvoh |
| Intercept Pharmaceuticals, INC. | $133.72 | 2019-2024 | |
| Redhill Biopharma INC. | $108.42 | 2021-2024 | Talicia |
| Qol Medical, LLC | $85.69 | 2022-2023 | Sucraid |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $82.82 | 2021-2024 | Zeposia |
| Organon LLC | $64.82 | 2023-2025 | Hadlima |
| Shionogi INC | $54.96 | 2019 | |
| Vivus LLC | $43.26 | 2024-2025 | Qsymia |
| Ironwood Pharmaceuticals, INC | $41.04 | 2021-2023 | Linzess |
| Amgen INC. | $37.39 | 2021 | |
| Braintree Laboratories, INC. | $32.09 | 2021-2024 | Suflave |
| Aimmune Therapeutics, INC. | $27.45 | 2025 | Vowst, Zenpep |
| Biocon Biologics INC | $27.14 | 2024 | Hulio |
| Intra-Sana Laboratories | $22.20 | 2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Ipsen Biopharmaceuticals, INC | $21.06 | 2025 | Iqirvo |
| Nestle Healthcare Nutrition INC. | $18.53 | 2023 | |
| Novo Nordisk INC | $18.29 | 2025 | Wegovy |
| Ferring Pharmaceuticals INC. | $18.21 | 2024 | Rebyota |
| Exact Sciences Corporation | $15.86 | 2024 | Cologuard Collection Kit |
| Celltrion USA INC. | $14.46 | 2025 | Vegzelma |
| Shield Therapeutics INC | $13.58 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dennis Riff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.